Biofiles Issue 4-5

Insulin-Like Growth Factors

LONG®R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications

Download article
LONG®R3IGF-I is a recombinant analog of human insulin-like growth factor-I (IGF-I) that has been specifically engineered for the enhancement of cell culture performance. LONG®R3IGF-I is more biologically potent in vitro than either insulin or native IGF-I and has been shown to significantly increase recombinant protein production. It is ideal for both research and large-scale culture systems utilizing serum-free or low-level serum applications.
LONG®R3IGF-I is specifically designed and manufactured exclusively for the research and industrial cell culture market for distribution by SAFC Biosciences.

LONG®R3IGF-I: Better science for better cell culture

Recombinant human insulin and other growth factors are essential for long-term growth and proliferation of cell lines. Although insulin is used as a growth factor in cell culture, its primary use is as a therapeutic drug for the treatment of diabetes. This has led to supply and availability issues for research and industrial cell culture users. In contrast, LONG®R3IGF-I is a dedicated raw material manufactured exclusively for cell culture applications providing a consistent, compliant and reliable alternative to recombinant insulin. It is not subject to market fluctuations and shortages as is recombinant insulin.

Proven science to maximize cell culture performance

Increase cell density, maintain higher viability and extend culture duration

Prolonged cell culture activity through greater stability

Regulatory compliant cGMP and animal free

Product Description Source Recombinant Host Physical Form Assay Cell Type Affected Product Number
LONGR3 IGF-I human Escherichia coli Lyphilized Powder ≥95% SDS-PAGE - 85580C -
Test Specification
Appearance Lyophilized white/creamy crystalline powder or a clear liquid
Endotoxin < 0.10 EU/μ protein
Bioburden Total viable aerobic count ≤100 cfu/mL
Biological Activity ED50 <10 ng/mL (Bioassay assessing the stimulation of protein synthesis in L6 myoblasts)
Concentration 0.9-1.1 mg/mL by reverse-phase HPLC
Identity Confirmed by N-terminal sequence analysis and reverse-phase HPLC (18 residues >95% single sequence)
Purity A single band ≥95% as determined by SDS-PAGE

Enlarge Enlarge Enlarge
Graph 1-3. Growth, viability and production data for insulin versus LONG®R3IGF-I. CHOK1 cells producing a recombinant protein were adapted to growth in protein-free media. Cells were cultured in spinner flasks in serum-free medium (60 mL) containing either insulin at 10 mg/L, LONG®R3IGF-I at 50 µg/L or no growth factor for a period of 11 days in a modified fed-batch process.
Graph 4. Growth data for insulin, native IGF-I and LONG®R3IGF-I. HEK 293 cells were adapted to growth in a protein-free media. Cells were cultured in 250 mL shaker flasks in serum-free medium (60 mL) containing either native IGF-I at 100 µg/L, insulin at 1 mg/L, LONG®R3IGF-I at 100 µg/L or no growth factor for a period of 10 days in a batch process.
Graph 5. LONG R3IGF-I resulted in increased cell growth, viability and productivity (data not shown).
LONG ® is a registered trademark of Novozymes Biopharma AU. Covered by the following patent assigned to Novozymes Biopharma AU: US patent 5,330,971.
PER.C6® is a registered tradmark of Crucell N.V.